Analysts expect Xeris Pharmaceuticals to report Q3 2026 revenue of $60.5 million and EPS of $0.02, while the current stock price of $3.55 remains significantly below the $7.50 average analyst price target.
Investors are primarily focused on the growth trajectory of Gvoke and the commercial scale-up of Recorlev to assess the path toward sustained profitability.
Recent quarters have shown narrowing losses as the company optimizes its sales force and benefits from increased market share in the rescue glucagon and Cushing’s syndrome segments.
Strong demand for Keveyis and potential updates on the XeriSol and XeriJect formulation platforms are also key drivers for the quarter's performance.